Cancer survivor rates are tragic stories of those who did not survive are invoked on both sides of the health care debate? Does reform promise to treat the untreated or will it threaten new and exciting technologies. Dr. Nicholas Vogelzang now directs research for U.S. Oncology - the parent company of the Comprehensive Cancer Centers of Nevada and he previously headed the Nevada Cancer Institute. Vogelzang gives us his take on how cancer treatment fits into the reform debate.
You won’t find a paywall here. Come as often as you like — we’re not counting. You’ve found a like-minded tribe that cherishes what a free press stands for. If you can spend another couple of minutes making a pledge of as little as $5, you’ll feel like a superhero defending democracy for less than the cost of a month of Netflix.